Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | BCKDK | O14874 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295172 | 0.85 | PTGER4 (0.48) | PTGER4ALDH1A1KDM4EHPGDL3MBTL1 | |
| SCHEMBL4410121 | 0.83 | PTGER4 (0.52) | PTGER4ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2299912 | 0.80 | PTGER4 (0.47) | PTGER4ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2300382 | 0.78 | PTGER4 (0.46) | PTGER4METAP2ALDH1A1KDM4EHPGD | |
| SCHEMBL2300372 | 0.78 | PTGER4 (0.46) | PTGER4ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL9654566 | 0.78 | PTGER4 (0.47) | PTGER4METAP2LMNA | |
| SCHEMBL9654877 | 0.76 | PTGER4 (0.46) | PTGER4KDM4EL3MBTL1MAPK1 | |
| SCHEMBL14458092 | 0.74 | PTGER4 (0.40) | PTGER4PDE10AALDH1A1KDM4EHPGD | |
| SCHEMBL11967633 | 0.73 | CASP3 (0.44) | PTGER4ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL9606731 | 0.73 | KDM4E (0.43) | PTGER4PDE10ADHODHALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | OPRK1, OPRD1, FFAR1 | PTGER4 170/4885PDE10A 272/4885METAP2 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.